ESC Study Group of Sports Cardiology Position Paper on adverse cardiovascular effects of doping in athletes

European Journal of Preventive Cardiology

Volumn 13, Issue 5, 2006, Pages 687-694

  Deligiannis, Asterios ^a   Bjã¶rnstad, Hans ^b   Carre, Francois ^c   Heidbã¼chel, Hein ^d   Kouidi, Evangelia ^a   Panhuyzen Goedkoop, Nicole M ^e   Pigozzi, Fabio ^f   Schã¤nzer, Wilhelm ^g   Vanhees, Luc ^h  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c Unitã Biologie et Mãdecine du Sport   (France)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSITY OF ROME FORO ITALICO   (Italy)

^g GERMAN SPORT UNIVERSITY COLOGNE   (Germany)

^h Department of Rehabilitation Sciences ^*  (Belgium)

Author keywords

cardiovascular side effects; doping; sports

Indexed keywords

AMPHETAMINE; ANABOLIC AGENT; ANALGESIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAMETHASONE; CAFFEINE; CANNABINOID; CENTRAL STIMULANT AGENT; CHORIONIC GONADOTROPIN; COCAINE; COLESTIPOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ERYTHROPOIETIN; ESMOLOL; FLUINDOSTATIN; GLUCOCORTICOID; LOCAL ANESTHETIC AGENT; MORPHINE; NARCOTIC AGENT; PEPTIDE HORMONE; PLASMA SUBSTITUTE; REPROTEROL; SOMATOMEDIN C; TESTOSTERONE; TOBACCO SMOKE; UNINDEXED DRUG;

ANXIETY; ATHEROGENESIS; ATHLETE; BLOOD PRESSURE; BODY WEIGHT; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CORONARY ARTERY CONSTRICTION; DOPING; DRUG ABUSE; DRUG SENSITIVITY; DRUG USE; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HEART MUSCLE INJURY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIPID BLOOD LEVEL; MUSCLE MASS; PHYSICIAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SPORT; THROMBOGENESIS; THROMBOSIS; WEIGHT REDUCTION;

ADRENERGIC AGENTS; ADRENERGIC BETA-ANTAGONISTS; ANABOLIC AGENTS; CARDIOVASCULAR DISEASES; CENTRAL NERVOUS SYSTEM STIMULANTS; DOPING IN SPORTS; EUROPE; HORMONES; HUMANS; NARCOTICS;

EID: 33748991139     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1097/01.hjr.0000224482.95597.7a     Document Type: Article

References (99)

1. World Anti-Doping Agency. The International Olympic Committee Anti-Doping Rules applicable to the Games of the XXVIII Olympiad in Athens in 2004. Lausanne: WADA; June 2004, p. 3. Available at website http://www.wada-ama.org/ [Accessed 26 December 2005].
2. World Anti-Doping Agency. The World Anti-Doping Code – The 2005 prohibited list, International standard. Lausanne: WADA; September 2004. Available at website http://www.wada-ama.org/ [Accessed 26 December 2005].
3. Wagner J. Enhancement of athletic performance with drugs. An overview. Sports Med 1991; 12: 250–265.
4. Labrie F, Luu-The V, Calvo E, Martel C, Cloutier J, Gauthier S, et al Tetrahydrogestrinone induces a genomic signature typical of a potent anabolic steroid. J Endocrinol 2005; 184: 427–433.
5. Sullivan ML, Martinez CM, Gennis P, Gallagher EJ. The cardiac toxicity of anabolic steroids. Prog Cardiovasc Dis 1998; 41: 1–15.
6. McCarthy K, Tang AT, Dalrymple-Hay MJ, Haw MP. Ventricular thrombosis and systemic embolism in bodybuilders: etiology and management. Ann Thorac Surg 2000; 70: 658–660.
7. Thiblin I, Lindquist O, Rajs J. Cause and manner of death among users of anabolic androgenic steroids. J Forensic Sci 2000; 45: 16–23.
8. Fineschi V, Baroldi G, Monciotti F, Paglicci Reattelli L, Turillazzi E. Anabolic steroid abuse and cardiac sudden death: a pathologic study. Arch Pathol Lab Med 2001; 125: 253–255.
9. Deligiannis A. Cardiac side effects of anabolics. Osterreichisches J Sportsmedizin 2002; 2: 35–37.
10. Melchert RB, Welder AA. Cardiovascular effects of androgenic-anabolic steroids. Med Sci Sports Exerc 1995; 27: 1252–1262.
11. Glazer G. Atherogenic effects of anabolic steroids on serum lipid levels. A literature review. Arch Intern Med 1991; 151: 1925–1933.
12. Thompson PD, Cullinane EM, Sady SP, Chenevert C, Saritelli AL, Sady MA, et al Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. JAMA 1989; 261: 1165–1168.
13. Hartgens F, Rietjens G, Keizer HA, Kuipers H, Wolffenbuttel B.H., Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a). Br J Sports Med 2004; 38: 253–259.
14. Applebaum-Bowden D, Haffner SM, Hazzard WR. The dyslipoproteinemia of anabolic steroid therapy: increase in hepatic triglyceride lipase precedes the decrease in high density lipoprotein2 cholesterol. Metabolism 1987; 36: 949–952.
15. Cohen LI, Hartford CG, Rogers GG. Lipoprotein (a) and cholesterol in body builders using anabolic androgenic steroids. Med Sci Sports Exerc 1996; 28: 176–179.
16. Kennedy MC, Lawrence C. Anabolic steroid abuse and cardiac death. Med J Aust 1993; 158: 346–348.
17. McCrohon JA, Jessup W, Handelsman DJ, Celermajer DS. Androgen exposure increases human monocyte adhesion to vascular endothelium and endothelial cell expression of vascular cell adhesion molecule-1. Circulation 1999; 99: 2317–2322.
18. McCrohon JA, Death AK, Nakhla S, Jessup W, Handelsman DJ, Stanley KK, et al Androgen receptor expression is greater in macrophages from male than from female donors. A sex difference with implications for atherogenesis. Circulation 2000; 101: 224–226.
19. Ferenchick G, Schwartz D, Ball M, Schwartz K. Androgenic-anabolic steroid abuse and platelet aggregation: a pilot study in weight lifters. Am J Med Sci 1992; 303: 78–82.
20. Pernot C, Hartgens F, Keizer HA. Effects of self-administration of high doses androgenic-anabolic steroid on fibrinolytic activity in non elite bodybuilders Fibrinolysis 1996; 10(suppl 2):53–54.
21. Nieminen MS, Ramo MP, Viitasalo M, Heikkila P, Karjalainen J, Mantysaari M, et al Serious cardiovascular side effects of large doses of anabolic steroids in weight lifters. Eur Heart J 1996; 17: 1576–1583.
22. Ferenchick GS, Hirokawa S, Mammen EF, Schwartz KA. Anabolic-androgenic steroid abuse in weight lifters: evidence for activation of the hemostatic system. Am J Hematol 1995; 49: 282–288.
23. Sader MA, Griffiths KA, McCredie RJ, Handelsman DJ, Celermajer DS. Androgenic anabolic steroids and arterial structure and function in male bodybuilders. J Am Coll Cardiol 2001; 37: 224–230.
24. McCredie RJ, McCrohon JA, Turner L, Griffiths KA, Handelsman DJ, Celermajer DS. Vascular reactivity is impaired in genetic females taking high-dose androgens. J Am Coll Cardiol 1998; 32: 1331–1335.
25. Herman SM, Robinson JT, McCredie RJ, Adams MR, Boyer MJ, Celermajer DS. Androgen deprivation is associated with enhanced endothelium-dependent dilatation in adult men. Arterioscler Thromb Vasc Biol 1997; 17: 2004–2009.
26. Appell HJ, Heller-Umpfenbach B, Feraudi M, Weicker H. Ultrastructural and morphometric investigations on the effects of training and administration of anabolic steroids on the myocardium of guinea pigs. Int J Sports Med 1983; 4: 268–274.
27. Takala TE, Ramo P, Kiviluoma K, Vihko V, Kainulainen H, Kettunen R. Effects of training and anabolic steroids on collagen synthesis in dog heart. Eur J Appl Physiol Occup Physiol 1991; 62: 1–6.
28. Behrendt H, Boffin H. Myocardial cell lesions caused by an anabolic hormone. Cell Tissue Res 1977; 181: 423–426.
29. Hausmann R, Hammer S, Betz P. Performance enhancing drugs (doping agents) and sudden death–a case report and review of the literature. Int J Legal Med 1998; 111: 261–264.
30. Luke JL, Farb A, Virmani R, Sample RH. Sudden cardiac death during exercise in a weight lifter using anabolic androgenic steroids: pathological and toxicological findings. J Forensic Sci 1990; 35: 1441–1447.
31. Karch SB, Billingham ME. Myocardial contraction bands revisited. Hum Pathol 1986; 17: 9–13.
32. Zaugg M, Jamali NZ, Lucchinetti E, Xu W, Alam M, Shafiq SA, et al Anabolic-androgenic steroids induce apoptotic cell death in adult rat ventricular myocytes. J Cell Physiol 2001; 187: 90–95.
33. McKillop G, Todd IC, Ballantyne D. The effects of body building and anabolic steroids on left ventricular structure and function. J Cardiovasc Technol 1989; 8: 23–29.
34. Dickerman RD, Schaller F, Zachariah NY, McConathy WJ. Left ventricular size and function in elite bodybuilders using anabolic steroids. Clin J Sport Med 1997; 7: 90–93.
35. Karila TA, Karjalainen JE, Mantysaari MJ, Viitasalo MT, Seppala TA. Anabolic androgenic steroids produce dose-dependant increase in left ventricular mass in power atheletes, and this effect is potentiated by concomitant use of growth hormone. Int J Sports Med 2003; 24: 337–343.
36. Palatini P, Giada F, Garavelli G, Sinisi F, Mario L, Michieletto M, et al Cardiovascular effects of anabolic steroids in weight-trained subjects. J Clin Pharmacol 1996; 36: 1132–1140.
37. Deligiannis A, Zahopoulou E, Mandroukas K. Echocardiographic study of cardiac dimensions and function in weight lifters and bodybuilders. Int J Sports Cardiol 1988; 5: 24–32.
38. Stolt A, Karila T, Viitasalo M, Mantysaari M, Kujala UM, Karjalainen J. QT interval and QT dispersion in endurance athletes and in power athletes using large doses of anabolic steroids. Am J Cardiol 1999; 84: 364–366.
39. Nottin S, Nguyen LD, Terbah M, Obert P. Cardiovascular effects of androgenic anabolic steroids in male bodybuilders determined by tissue Doppler imaging. Am J Cardiol 2006; 97: 912–915.
40. Urhausen A, Albers T, Kindermann W. Are the cardiac effects of anabolic steroid abuse in strength athletes reversible? Heart 2004; 90: 496–501.
41. Svorcik C, Bicikova L. Effect of drugs on the stimulation threshold of the human heart. Cor Vasa 1978; 20: 184–195.
42. Neumann F, Schneck B. Pharmakotherapie mit hormonen. In: Forth W, Henschler D, Rummel W, editors. Pharmakologie und Toxikologie. Mannheim, Wien, Zurich: Bibliographisches Institut and FA Brockhaus; 1987. pp. 396–423.
43. Sullivan ML, Martinez CM, Gallagher EJ. Atrial fibrillation and anabolic steroids. J Emerg Med 1999; 17: 851–857.
44. Hartmann G, Addicks K, Donike M, Schanzer W. Testosterone application influences sympathetic activity of intracardiac nerves in non-trained and trained mice. J Auton Nerv Syst 1986; 17: 85–100.
45. Baker PJ, Ramey ER, Ramwell PW. Androgen-mediated sex differences of cardiovascular responses in rats. Am J Physiol 1978; 235: H242–246.
46. Kuipers H, Wijnen JA, Hartgens F, Willems SM. Influence of steroids on body composition, blood pressure, lipid profile and liver function in bodybuilders. Int J Sports Med 1991; 12: 413–418.
47. Grace F, Sculthorpe N, Baker J, Davies B. Blood pressure and rate pressure product response in males using high-dose anabolic androgenic steroids (AAS). J Sci Med Sport 2003; 6: 307–312.
48. Hartgens F, Cheriex EC, Kuipers H. Prospective echocardiographic assessment of androgenic-anabolic steroids effects on cardiac structure and function in strength athletes. Int J Sports Med 2003; 24: 344–351.
49. Colao A, Marzullo P, Di Somma C, Lombardi G. Growth hormone and the heart. Clin Endocrinol 2001; 54: 137–154.
50. Audran M, Gareau R, Matecki S, Durand F, Chenard C, Sicart MT, et al Effects of erythropoietin administration in training athletes and possible indirect detection in doping control. Med Sci Sports Exerc 1999; 31: 639–645.
51. Kicman AT, Cowan DA. Peptide hormones and sport: misuse and detection. Br Med Bull 1992; 48: 496–517.
52. Vergouwen PC, Collee T, Marx JJ. Haematocrit in elite athletes. Int J Sports Med 1999; 20: 538–541.
53. Wagner KF, Katschinski DM, Hasegawa J, Schumacher D, Meller B, Gembruch U, et al Chronic inborn erythrocytosis leads to cardiac dysfunction and premature death in mice overexpressing erythropoetin. Blood 2001; 97: 536–542.
54. Noakes TD. Tainted glory. Doping and athletic performance. N Engl J Med 2004; 151: 847–849.
55. Prather ID, Brown DE, North P, Wilson JR. Clenbuterol: a substitute for anabolic steroids? Med Sci Sports Exerc 1995; 27: 1118–1121.
56. Fisher AA, Davis MW, McGill DA. Acute myocardial infarction associated with albuterol. Ann Pharmacother 2004; 38: 2045–2049.
57. Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest 2004; 125: 2309–2321.
58. Chodorowski Z, Sein-Anand J. Acute poisoning with clenbuterol–a case report. Przegl Lek 1997; 54: 763–764.
59. Fuster D, Escher G, Vogt B, Ackermann D, Dick B, Frey BM, et al Furosemide inhibits 11-βhydroxysteroid dehydrogenase type 2. Endocrinol 1998; 139: 3849–3854.
60. Laties V, Weiss B. The amphetamine margin in sports. Federation Proc 1981; 40: 2689–2692.
61. George A. Central nervous system stimulants. Bailliere's Clin Endocrinol Metab 2000; 14: 79–88.
62. Smith HJ, Roche AH, Jausch MF, Herdson PB. Cardiomyopathy associated with amphetamine administration. Am Heart J 1976; 91: 792–797.
63. Hong R, Matsuyama E, Nur K. Cardiomyopathy associated with the smoking of crystal methamphetamine. JAMA 1991; 265: 1152–1154.
64. Cregler L, Mark H. Medical complications of cocaine abuse. N Engl J Med 1986; 315: 1495–1500.
65. Cregler L. Substance abuse in sports: The impact of cocaine, alcohol, steroids, and other drugs on the heart. In: Williams RA, editor. The athlete and heart disease: diagnosis, evaluation and management. Philadelphia: Lippincott Williams and Wilkins; 1999. pp. 131–153.
66. Covert J. Illicit drugs and the athlete. Am Pharm 1986; 26: 39–45.
67. O'Leary ME. Inhibition of human ether-a-go-go potassium channels by cocaine. Mol Pharmacol 2001; 59: 269–277.
68. Brody S, Slovis C, Wrenn K. Cocaine – related medical problems. Consecutive series of 233 patients. Am J Med 1990; 88: 325–331.
69. Billman GE. Cocaine: a review of its toxic actions on cardiac function. Crit Rev Toxicol 1995; 25: 113–132.
70. Haller C, Benowitz NN. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med 2000; 343: 1833–1838.
71. Zahn K, Li R, Purssell R. Cardiovascular toxicity after ingestion of ‘Herbal Ecstacy’. J Emerg Med 1999; 17: 289–291.
72. Zaacks S, Klein L, Tan C, Rodriguez E, Leikin J. Hypersensitivity myocarditis associated with ephedra use. J Toxicol Clin Toxicol 1999; 37: 485–489.
73. Samenuk D, Link MS, Homoud MK, Contreras R, Theoharides TC, Wang PJ, et al Adverse cardiovascular events temporally associated with ma huang, an herbal source of ephedrine. Mayo Clin Proc 2002; 77: 12–16.
74. Chyka P, McCommon S. Reporting of adverse drug reactions by poison control centres in the US. Drug Saf 2000; 23: 87–93.
75. Erjavec M, Coda B, Nguyen Q, Donaldson G, Rister L, Shen D. Morphine–fluoxetine interactions in healthy volunteers: analgesia and side effects. J Clin Pharmacol 2000; 40: 1286–1295.
76. Campos DR, Yonamine M, de Moraes Moreau RL. Marijuana as doping in sports. Sports Med 2003; 33: 395–399.
77. Bachs L, Morland H. Acute cardiovascular fatalities following cannabis use. Forensic Sci Int 2001; 124: 200–203.
78. Belvisi MG, Brown TJ, Wicks S, Foster ML. New glucocorticosteroids with an improved therapeutic ratio? Pulm Pharmacol Ther 2001; 14: 221–227.
79. Sholter DE, Armstrong PW. Adverse effects of corticosteroids on the cardiovascular system. Can J Cardiol 2000; 16: 505–511.
80. Spence J, Gauvin L. Drug and alcohol use by Canadian University athletes: a national survey. J Drug Educ 1996; 26: 275–287.
81. Kagan A, Yano K, Rhoads GG, McGee DL. Alcohol and cardiovascular disease: the Hawaiian experience Circulation 1981; 64: III 27–31.
82. Wadler G, Hainline B. Drugs and the athlete. Philadelphia: F.A. Davis; 1989.
83. Williams M. Beyond training. Champaign, Illinois: Leisure Press; 1989.
84. Deutscher S. The effects of heavy drinking on ischemic heart disease. Prim Cardiol 1986; 12: 40–48.
85. Stason WB, Neff RK, Miettinen OS, Jick H. Alcohol consumption and nonfatal myocardial infarction. Am J Epidemiol 1976; 104: 603–608.
86. Vogel RA. Alcohol, heart disease, and mortality: a review. Rev Cardiovasc Med 2002; 3: 7–13.
87. Taskinen MR, Nikkila EA, Valimaki M, Sane T, Kuusi T, Kesaniemi A, et al Alcohol-induced changes in serum lipoproteins and in their metabolism. Am Heart J 1987; 113: 458–464.
88. Clarkson PM, Thompson HS. Drugs and sport. Research findings and limitations. Sports Med 1997; 24: 366–384.
89. Vanhees L, Fagard R, Lijnen P, Amery A. Effect of antihypertensive medication on endurance exercise capacity in hypertensive sportsmen. J Hypertens 1991; 9: 1063–1068.
90. Vanhees L, Defoor JG, Schepers D, Lijnen P, Peeters BY, Lacante PH, et al Effect of bisoprolol and atenolol on endurance exercise capacity in healthy men. J Hypertens 2000; 181: 35–43.
91. Schmid P. Use of beta receptor blockers in performance sports. Wien Med Wochenschr 1990; 140: 184–188.
92. Graham T. Caffeine and exercise: metabolism, endurance and performance. Sports Med 2001; 31: 785–807.
93. Josephson G, Stine R. Caffeine intoxication: a case of paroxysmal atrial tachycardia. JACEP 1976; 5: 776–778.
94. Glover ED, Edmundson EW, Edwards SW, Schroeder KL. Implications of smokeless tobacco use among athletes. Physician Sports Med 1986; 14: 95–105.
95. Connoly G, Orleans C, Kogan M. Use of smokeless tobacco in major-league baseball. N Engl J Med 1988; 318: 1281–1284.
96. Chung MK. Vitamins, supplements, herbal medicines, and arrhythmias. Cardiol Rev 2004; 12: 73–84.
97. Saliba W, Erdogan O, Niebauer M. Polymorphic ventricular tachycardia in a woman taking cesium chloride. Pacing Clin Electrophysiol 2001; 24: 515–517.
98. Appleby M, Fisher M, Martin M. Myocardial infarction, hyperkalaemia and ventricular tachycardia in a young male body-builder. Int J Cardiol 1994; 44: 171–174.
99. Yates K, O'Connor A, Horsley C. ‘Herbal Ecstacy’: a case series of adverse reactions. NZ Med J 2000; 113: 315–317.